John Bencich
2022
In 2022, John Bencich earned a total compensation of $1.5M as Chief Executive Officer at OncoGenex Pharmaceuticals, a 7% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $223,125 |
|---|---|
| Option Awards | $358,670 |
| Salary | $510,000 |
| Stock Awards | $413,000 |
| Total | $1,504,795 |
Bencich received $510K in salary, accounting for 34% of the total pay in 2022.
Bencich also received $223.1K in non-equity incentive plan, $358.7K in option awards and $413K in stock awards.
Rankings
In 2022, John Bencich's compensation ranked 2,226th out of 5,756 executives tracked by ExecPay. In other words, Bencich earned more than 61.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,226 out of 5,756 | 61st |
Division Manufacturing | 1,205 out of 3,133 | 62nd |
Major group Chemicals And Allied Products | 528 out of 1,419 | 63rd |
Industry group Drugs | 486 out of 1,320 | 63rd |
Industry In Vitro and In Vivo Diagnostic Substances | 6 out of 29 | 79th |
Source: SEC filing on April 28, 2023.
Bencich's colleagues
We found two more compensation records of executives who worked with John Bencich at OncoGenex Pharmaceuticals in 2022.
News
OncoGenex Pharmaceuticals CEO John Bencich's 2022 pay slips 7% to $1.5M
April 28, 2023
OncoGenex Pharmaceuticals CEO John Bencich's 2021 pay jumps 82% to $1.6M
April 21, 2022
OncoGenex Pharmaceuticals CEO Richard Stewart's 2020 pay jumps 30% to $1M
March 30, 2021
OncoGenex Pharmaceuticals CEO Richard Stewart's 2019 pay falls 27% to $797K
April 2, 2020
OncoGenex Pharmaceuticals CEO Richard Stewart's 2018 pay jumps 423% to $1.1M
March 28, 2019